Wednesday, 18 March 2026

Redesigning oncology clinical trials with agentic AI

 

Over the past few years, artificial intelligence (AI) has placed an increasing role in cancer research. AI tools "can be used to help improve the next generation of treatment options for patients in key tumour areas, leveraging real-life data...to combine new and existing therapies."   At the recent European Society of Medical Oncology (ESMO) Targeted Anticancer Therapies Congress, the following notion was brought forth: "AI is not the future - it is the present.  By learning how to best harness its power, we can help increased the speed and efficiency of personalized care delivery."  

Click here to learn more. 

Programme details

Reis-Filho J. Transforming R&D with AI. ESMO Targeted Anticancer Therapies Congress 2026 - Educational Session: The agentic AI advantage: Optimising oncology clinical trials

No comments:

Post a Comment